Nevro Corp - Understand $nvro stock

$NVRO Market Cap: $155.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$419.1M

TTM

Gross Margin

67.94%

TTM

Net Earnings

-$69.31M

TTM

Current Assets

$479.2M

Q3 2024

Current Liabilities

$95.41M

Q3 2024

Current Ratio

502.28%

Q3 2024

Total Assets

$595.6M

Q3 2024

Total Liabilities

$322.0M

Q3 2024

Book Value

$273.6M

Q3 2024

Cash

$71.98M

Q3 2024

P/E

-2.238

Nov 29, 2024 EST

Free Cash Flow

-$56.61M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$425.2M	$406.4M	$386.9M	$362.0M	$390.3M	$387.3M	$326.7M	$228.5M	$69.61M	$32.57M	$23.50M	$18.15M
YoY Change	4.63%	5.03%	6.87%	-7.23%	0.77%	18.56%	42.96%	228.28%	113.69%	38.61%	29.48%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$425.2M	$406.4M	$386.9M	$362.0M	$390.3M	$387.3M	$326.7M	$228.5M	$69.61M	$32.57M	$23.50M	$18.15M
Cost Of Revenue	$135.1M	$130.0M	$120.9M	$112.1M	$121.9M	$114.0M	$98.98M	$75.43M	$28.12M	$11.28M	$9.473M	$7.527M
Gross Profit	$290.1M	$276.4M	$266.0M	$249.9M	$268.4M	$273.3M	$227.7M	$153.1M	$41.49M	$21.30M	$14.03M	$10.62M
Gross Profit Margin	68.22%	68.01%	68.76%	69.02%	68.76%	70.57%	69.7%	66.99%	59.6%	65.38%	59.69%	58.53%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$334.7M	$322.1M	$309.3M	$267.2M	$305.8M	$266.6M	$219.7M	$142.4M	$82.47M	$29.78M	$18.83M	$14.09M
YoY Change	3.9%	4.15%	15.78%	-12.64%	14.71%	21.35%	54.26%	72.69%	176.96%	58.11%	33.62%
% of Gross Profit	115.39%	116.56%	116.26%	106.9%	113.96%	97.54%	96.49%	93.04%	198.79%	139.83%	134.26%	132.67%
Research & Development	$54.42M	$53.07M	$47.67M	$45.60M	$59.02M	$48.46M	$37.56M	$33.73M	$21.38M	$19.82M	$20.35M	$15.66M
YoY Change	2.55%	11.33%	4.53%	-22.73%	21.79%	29.02%	11.36%	57.74%	7.86%	-2.56%	29.93%
% of Gross Profit	18.76%	19.2%	17.92%	18.25%	21.99%	17.73%	16.5%	22.03%	51.54%	93.09%	145.04%	147.41%
Depreciation & Amortization	$6.800M	$6.200M	$4.900M	$4.800M	$4.600M	$3.900M	$2.500M	$1.717M	$614.0K	$96.00K	$47.00K	$40.00K
YoY Change	9.68%	26.53%	2.08%	4.35%	17.95%	56.0%	45.6%	179.64%	539.58%	104.26%	17.5%
% of Gross Profit	2.34%	2.24%	1.84%	1.92%	1.71%	1.43%	1.1%	1.12%	1.48%	0.45%	0.34%	0.38%
Operating Expenses	$389.4M	$270.2M	$377.0M	$312.8M	$364.8M	$48.46M	$37.56M	$176.2M	$103.9M	$49.60M	$39.18M	$29.75M
YoY Change	44.1%	-28.32%	20.53%	-14.27%	652.86%	29.02%	-78.68%	69.62%	109.38%	26.6%	31.68%
Operating Profit	-$99.31M	$6.164M	-$110.9M	-$62.85M	-$96.48M	-$41.74M	-$29.58M	-$23.08M	-$62.37M	-$28.31M	-$25.15M	-$19.13M
YoY Change	-1711.1%	-105.56%	76.5%	-34.85%	131.13%	41.12%	28.15%	-62.99%	120.33%	12.54%	31.47%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$8.014M	$6.432M	-$19.78M	-$18.80M	$10.93M	$10.40M	$9.902M	$6.394M	$2.732M	$16.00K	$200.0K	$100.0K
YoY Change	24.6%	-132.52%	5.2%	-271.99%	5.1%	5.04%	54.86%	134.04%	16975.0%	-92.0%	100.0%
% of Operating Profit		104.35%
Other Income/Expense, Net	-$586.0K	$511.0K	-$114.0K	-$495.0K	-$697.0K	-$1.164M	$1.067M	-$1.097M	-$1.741M	-$1.880M	-$654.0K	$186.0K
YoY Change	-214.68%	-548.25%	-76.97%	-28.98%	-40.12%	-209.09%	-197.27%	-36.99%	-7.39%	187.46%	-451.61%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$97.86M	$4.264M	-$130.8M	-$82.20M	-$102.1M	-$48.44M	-$35.25M	-$30.16M	-$66.27M	-$30.20M	-$25.65M	-$18.81M
YoY Change	-2395.0%	-103.26%	59.16%	-19.48%	110.76%	37.41%	16.9%	-54.49%	119.41%	17.74%	36.41%
Income Tax	-$5.646M	$1.263M	$534.0K	$868.0K	$1.599M	$768.0K	$1.408M	$1.623M	$1.166M	$478.0K	$362.0K	$162.0K
% Of Pretax Income		29.62%
Net Earnings	-$92.20M	$3.000M	-$131.4M	-$83.07M	-$103.7M	-$49.21M	-$36.66M	-$31.78M	-$67.43M	-$30.68M	-$26.01M	-$18.97M
YoY Change	-3173.33%	-102.28%	58.14%	-19.89%	110.72%	34.23%	15.36%	-52.87%	119.79%	17.94%	37.15%
Net Earnings / Revenue	-21.69%	0.74%	-33.95%	-22.94%	-26.57%	-12.7%	-11.22%	-13.91%	-96.88%	-94.19%	-110.7%	-104.5%
Basic Earnings Per Share	-$2.56	$0.08	-$3.77	-$2.47
Diluted Earnings Per Share	-$2.56	$0.08	-$3.772M	-$2.466M	-$3.367M	-$1.635M	-$1.248M	-$1.116M	-$2.534M	-$1.233M	-$1.140M	-$833.3K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$322.7M	$374.4M	$362.0M	$588.0M	$237.8M	$264.5M	$269.3M	$276.4M	$193.7M	$176.8M	$56.50M	$30.60M
YoY Change	-13.8%	3.41%	-38.43%	147.27%	-10.09%	-1.78%	-2.57%	42.69%	9.56%	212.92%	84.64%
Cash & Equivalents	$104.2M	$120.4M	$34.71M	$44.60M	$65.40M	$51.30M	$42.80M	$41.40M	$87.00M	$25.30M	$12.40M	$5.600M
Short-Term Investments	$218.5M	$254.0M	$327.3M	$543.4M	$172.4M	$213.3M	$226.5M	$235.0M	$106.6M	$151.5M	$44.10M	$25.00M
Other Short-Term Assets	$10.15M	$9.984M	$5.185M	$4.200M	$9.800M	$6.600M	$6.500M	$5.900M	$4.000M	$2.900M	$1.500M	$2.800M
YoY Change	1.61%	92.56%	23.45%	-57.14%	48.48%	1.54%	10.17%	47.5%	37.93%	93.33%	-46.43%
Inventory	$118.7M	$99.64M	$93.52M	$83.30M	$91.60M	$92.00M	$98.10M	$85.20M	$62.40M	$14.90M	$10.10M	$9.600M
Prepaid Expenses
Receivables	$79.38M	$78.93M	$70.48M	$77.70M	$82.80M	$80.70M	$67.30M	$52.80M	$22.50M	$6.600M	$6.600M	$5.900M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$530.9M	$562.9M	$531.2M	$753.1M	$422.1M	$443.9M	$441.2M	$420.3M	$282.6M	$201.1M	$74.80M	$48.80M
YoY Change	-5.69%	5.97%	-29.46%	78.42%	-4.91%	0.61%	4.97%	48.73%	40.53%	168.85%	53.28%
Property, Plant & Equipment	$33.51M	$35.70M	$38.24M	$31.70M	$33.30M	$12.80M	$8.800M	$7.100M	$5.800M	$600.0K	$100.0K	$100.0K
YoY Change	-6.13%	-6.64%	20.63%	-4.8%	160.16%	45.45%	23.94%	22.41%	866.67%	500.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.762M	$3.770M	$5.099M	$4.600M	$14.30M	$6.500M	$4.100M	$3.200M	$2.800M	$700.0K	$500.0K	$200.0K
YoY Change	52.84%	-26.06%	10.85%	-67.83%	120.0%	58.54%	28.12%	14.29%	300.0%	40.0%	150.0%
Total Long-Term Assets	$104.8M	$39.47M	$43.34M	$36.30M	$47.50M	$19.20M	$12.90M	$10.30M	$8.600M	$1.400M	$600.0K	$300.0K
YoY Change	165.49%	-8.93%	19.39%	-23.58%	147.4%	48.84%	25.24%	19.77%	514.29%	133.33%	100.0%
Total Assets	$635.7M	$602.4M	$574.5M	$789.4M	$469.6M	$463.1M	$454.1M	$430.6M	$291.2M	$202.5M	$75.40M	$49.10M
YoY Change
Accounts Payable	$22.52M	$26.85M	$32.00M	$23.10M	$16.00M	$23.50M	$18.50M	$16.20M	$21.90M	$4.500M	$3.200M	$2.000M
YoY Change	-16.12%	-16.09%	38.52%	44.38%	-31.91%	27.03%	14.2%	-26.03%	386.67%	40.63%	60.0%
Accrued Expenses	$51.02M	$50.45M	$49.03M	$46.00M	$52.10M	$36.30M	$36.60M	$23.90M	$12.30M	$5.300M	$3.600M	$2.500M
YoY Change	1.12%	2.9%	6.59%	-11.71%	43.53%	-0.82%	53.14%	94.31%	132.08%	47.22%	44.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$168.8M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$83.38M	$79.21M	$82.20M	$239.2M	$70.60M	$62.40M	$58.00M	$42.20M	$36.40M	$10.80M	$7.900M	$5.200M
YoY Change	5.26%	-3.64%	-65.63%	238.81%	13.14%	7.59%	37.44%	15.93%	237.04%	36.71%	51.92%
Long-Term Debt	$211.5M	$186.9M	$151.3M	$141.8M	$160.3M	$152.4M	$145.0M	$138.1M	$19.70M	$19.50M	$0.00	$0.00
YoY Change	13.17%	23.5%	6.71%	-11.54%	5.18%	5.1%	5.0%	601.02%	1.03%
Other Long-Term Liabilities	$47.72M	$12.45M	$37.42M	$20.00M	$22.40M	$2.800M	$1.900M	$1.200M	$500.0K	$100.0K	$100.0K	$200.0K
YoY Change	283.22%	-66.72%	87.08%	-10.71%	700.0%	47.37%	58.33%	140.0%	400.0%	0.0%	-50.0%
Total Long-Term Liabilities	$259.2M	$199.3M	$188.7M	$161.8M	$182.7M	$155.2M	$146.9M	$139.3M	$20.20M	$19.60M	$100.0K	$200.0K
YoY Change	30.04%	5.61%	16.64%	-11.44%	17.72%	5.65%	5.46%	589.6%	3.06%	19500.0%	-50.0%
Total Liabilities	$342.6M	$278.5M	$270.9M	$401.0M	$253.3M	$217.6M	$204.9M	$181.5M	$56.60M	$30.40M	$8.000M	$5.500M
YoY Change	22.99%	2.81%	-32.44%	58.31%	16.41%	6.2%	12.89%	220.67%	86.18%	280.0%	45.45%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Basic Shares Outstanding	35.98M	35.32M	34.82M	33.68M	30.80M	30.05M	29.42M	28.49M	26.60M	4.487M	1.091M shares	902.7K shares
Diluted Shares Outstanding	35.98M	35.53M	34.82M	33.68M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $155.13 Million

About NEVRO CORP

Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,215 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES AtriCure, Inc. Cryoport, Inc. GLAUKOS Corp Integer Holdings Corp NUVASIVE INC Paragon 28, Inc. PROCEPT BioRobotics Corp TREACE MEDICAL CONCEPTS, INC. TransMedics Group, Inc.